Programs and Projects
Prostate Cancer Clinical Trials - University of Arizona
Agent: Polyphenon E
Contact: Frederick Ahmann, MD
DCP Program Director: Joe Tangrea, MPH, PhD
The purpose of this study is to evaluate the potential of polyphenon E as a chemopreventive agent for prostate cancer. Men with a diagnosis of prostate cancer who are considering surgical removal of the prostate gland (prostatectomy) may be eligible to participate in this study. Those taking part in the study will receive either polyphenon E or placebo for several weeks immediately before prostate surgery. The study is being conducted at the University of Arizona. The study is now open to accrual.
[This is a phase 2 randomized double-blind placebo controlled trial of the polyphenon E administered for 4-6 weeks in the presurgical period prior to prostatectomy in men with organ-confined adenocarcinoma of the prostate. The primary endpoint is to determine the bioavailability of green tea catechins in prostate tissue following 4-6 weeks of Polyphenon E intervention.]